PAHC (Phibro Animal Health) Growth Rank: 7 (As of Aug. 08, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PAHC Phibro Animal Health Corp PAHC
75 GF Score
Price $34.26
GF Value $29.54
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Phibro Animal Health Growth Rank?

Phibro Animal Health PAHC -3.41% 75 Growth Rank is 7 as of Aug. 08, 2026, which is at its 10-year median of 7.00. GuruFocus rates PAHC with a GF Score™ of 75/100 and a GF Value™ of $29.54 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Phibro Animal Health has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Phibro Animal Health Growth Rank Related Terms

PAHC vs PRGO, HROW, XERS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phibro Animal Health Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's Growth Rank distribution charts can be found below:

* The bar in red indicates where Phibro Animal Health's Growth Rank falls into.


PAHC
75GF Score
Phibro Animal Health Corp PAHC
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Phibro Animal Health (PAHC) has a Growth Rank of 7 as of Aug. 08, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Phibro Animal Health and its competitors. This is near median its historical median of 7.00. Over the past decade, Phibro Animal Health's Growth Rank has ranged from 2.00 to 9.00.
Is Phibro Animal Health's Growth Rank too high?
Phibro Animal Health's current Growth Rank of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. Overall, Phibro Animal Health has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's Growth Rank compare to PRGO and HROW?
Phibro Animal Health's Growth Rank of 7 can be compared against companies in the Drug Manufacturers industry. Historically, Phibro Animal Health's own Growth Rank has ranged from 2.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Phibro Animal Health and its competitors. Phibro Animal Health's current Growth Rank is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.54, compared to a current price of $34.26 — trading 16% above its estimated fair value. The current Growth Rank is 7, which is near median its 10-year median of 7.00. Phibro Animal Health's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current Growth Rank is 7 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Phibro Animal Health (PAHC) Overvalued in 2026?

Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued. The current stock price of $34.26 is trading 16% above its estimated GF Value™ of $29.54. GuruFocus considers Phibro Animal Health to be Modestly Overvalued.

Key valuation signals for PAHC:

  • Growth Rank: 7 (near median its 10-year median of 7.00)
  • GF Value™: $29.54 vs. price of $34.26 (16% above fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Phibro Animal Health Business Description

Other Exchanges PB8:Germany
Address 300 Frank W. Burr Boulevard, Suite 21, 3rd Floor, Glenpointe Centre East, Teaneck, NJ, USA, 07666-6712
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
75GF Score

Get the complete analysis for PAHC

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.26
Price
$29.54
GF Value